📰 Genentech News
Page 211 - Genentech News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Genentech. Real-time updates on events, politics, business and more.
January 23, 2023
Last year, the FDA approved almost a dozen novel cancer drugs and expanded indications for many more, while growing agency scrutiny led to numerous withdrawals.
January 22, 2023
Oregon lawmakers have several weeks to come up with ways to encourage the making of semiconductors and educating future tech workers like Emily Mom.
January 21, 2023
Cancer continues to be a hot area of investment, and it’s the therapeutic focus of several biotech companies that have closed recent rounds of financing. Meanwhile, the investment arm of a big pharmaceutical company has an infusion of new cash to deploy in therapeutic and digital investments.
January 20, 2023
On January 6, 2023, Genentech and Tanvex reached a settlement in principle to resolve all claims with respect to Genentech’s BCPIA complaint. As we previously reported, Genentech filed...
January 20, 2023
The Business Research Company’s Biosimilar Lymphocyte Modulator Global Market Report 2023 – Market Size, Trends, And Forecast 2023-2027
January 20, 2023
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMbrave050 study met its primary endpoint of recurrence-free survival (RFS) at the prespecified interim analysis. The study is evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as adjuvant treatment following surgery ...
January 19, 2023
Exelixis is a young commercial stage biopharma that is enjoying success with its CABOMETYX. Read more to see why I consider EXEL stock a near-term buy.
January 19, 2023
(RTTNews) - Pivotal Phase III IMbrave050 study, which investigated Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma or H...
January 19, 2023
SOUTH SAN FRANCISCO (dpa-AFX) - Pivotal Phase III IMbrave050 study, which investigated Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma or HCC at high risk of recurrence
January 19, 2023
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s DiseaseFirst Alzheimer’s patient imaged with PI-2620 in ADvance, the pivotal Phase 3 trialPI-2620 potentially best-in-class Tau PET tracer with high binding affinity and selectivity for aggregat...